#offerPrEP #PrEPworks

TDF/3TC for PrEP: the rationale and the evidence

Dr. Ioannis Hodges-Mameletzis

January 17, 2019



DISCLAIMER No conflicts of interest to declare

OVERVIEW

- What is WHO's position on TDF/3TC?
 - Current oral PrEP recommendation
 - EML
 - Rationale for TDF/3TC
 - Evidence base
- What is happening in other countries with PrEP implementation, including TDF/3TC?






What is PrEP?



NOT ONLY TRUVADA

Over 10 generic products (appropriate for PrEP) are WHO prequalified (TDF/FTC and TDF/3TC)

WHO RECOMMENDATION (2015)



WHO RECOMMENDATION (2015)

- PrEP is recommended for any person at *substantial* risk for HIV
- TDF-containing
 - TDF/FTC, TDF/3TC, or TDF monotherapy
- Daily dosing currently recommended for all populations
- Near future, event-driven PrEP ('on-demand') for MSM
 - 2 + 1 + 1 (Ipergay dosing)
- Not just a pill, but part of a package of combination HIV prevention and sexual health

WHO guidance documents available online at: <u>https://www.who.int/hiv/topics/prep/en/</u>

PROPHYLAXIS (Prep

IV INFFCTI

ECHNICAL BRIEF

THE

OF PREP





CLINICAL



TESTING

PROVIDERS




CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION

RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH

> SECOND EDITION 2016

WHO PrEP Implementation Tool (2017)



http://who.int/hiv/pub/prep/prep-implementation-tool

STI testing recommended during PrEP use



Also, PrEP always comes with a mandatory medical follow up every 3 months so you can get tested for other STDs and check on your sexual health in general!

The use of PrEP changes according to the country you live in Some countries like France have universal healthcare so PrEP is totally free, and in other like the United States, it will depend on your insurance.

Good to know: there are also organizations that can help you pay for PrEP if you have no insurance!

WHO MODEL LIST OF ESSENTIAL MEDICINES

- guide for development of national/institutional essential medicine lists
- updated/revised every two years by the WHO Expert Committee on Selection and Use of Medicines.
- 20th Essential Medicines List, published on 6 June 2017, marks the 40th anniversary of this flagship WHO tool to expand access to medicines.
- **433 drugs** deemed essential for addressing the most important public health needs globally.

PrEP is an essential medicine as of 2017

- TDF/3TC
- TDF/FTC
- TDF mono-therapy
- Full report accessible here: <u>http://apps.who.int/iris/</u> <u>bitstream/handle/10665/259481/9789241210157-</u> <u>eng.pdf?sequence=1</u>

Global	Regions 🗸						عربي	中文	English	Français	Русский	Español
	World Healt Organizatio	:h n										
	Health T	opics ~	Countries	•	News 🗸	Emergeno	cies ~		About	Us v		
			Es	sential med	icines and he	alth products	5					
Medicines and health products About us		ducts WH	WHO Model Lists of Essential Medicines				м	eetings & ev	ents			
		About us		The WHO Model Lists of Essential Medicines has been upda since 1977.			every two years					

Access and innovation The current versions are the 20th WHO Essential Medicines List (EML) and the 6th WHO Essential Medicines List for Children (EMLc) updated in March 2017. Regulation Publications The 2017 Expert Committee on the Selection and Use of **Essential Medicines** News Executive Summary pdf, 723kb - 40th ECDD Meeting on Cannabis and Contacts Cannabis-Related Substances Report of the 2017 Expert Committee **CURRENT LISTS** EML – 20th edition (March 2017, amended August 2017) EMLc – 6th edition (March 2017, amended August 2017)

Technics

RATIONALE


- COST
- SUPPLY CHAIN


- TDF/FTC as PrEP availability remains limited globally
 - Need to clarify use of TDF/3TC instead of TDF/FTC as PrEP
 - WHO Guidelines state that "Oral PrEP (containing TDF) should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination prevention approaches".
 - How should we interpret the guidelines?

Considerations

- What is the added-value (to public health and individual health) to undertake a non-inferiority PrEP RCT (TDF/FTC vs TDF/3TC)?
- What are the short-term and longer term benefits of implementing TDF/3TC within a health system (e.g. cost-saving in order to target resources to other services for key populations, e.g. optimised STI case management) ?

Chemical structure: very similar 3TC FTC





- The chemical structures of 3TC and FTC differ only by the presence in FTC of fluorine at the 5'-position of its cytosine ring
- 3TC and FTC are oxathiolane-cytosine analogs that selectively inhibit HIV replication.
- Like other NRTIs, 3TC and FTC must be triphosphorylated **intracellularly** before they can competitively inhibit endogenous deoxycytidine triphosphate (dCTP) and cause chain termination.

Evidence base for TDF/3TC as PrEP

1.Indirect evidence from systematic review of ART studies on interchangeability of 3TC and FTC (*WHO*, 2012, 2016)

2. Clinical trials of 3TC in prevention of mother-to-child transmission

3.WHO post-exposure prophylaxis guidelines

4. Animal and human pharmacokinetic studies

5.Direct evidence: phase I study of TDF/3TC as PrEP in MSM (ongoing Phase II) from Universidade Federal de Minas Gerais, Brazil (no HIV seroconversions)

Indirect evidence

 evidence on the safety and/or efficacy of (preexposure prophylaxis) drugs inferred from studies whose primary aim is not to directly assess these outcomes of interest

Spectrum of evidence reviewed

- Animal pharmacology
- Virus challenge studies
 - Rhesus macaques (rectal transmission)
 - Pigtail macaques (vaginal transmission)



- Human pharmacology
- Clinical trials (men, women, and transgender persons)
 - TDF alone
 - TDF/FTC
- Systematic reviews/metaanalyses
 - PrEP
 - ART

HIV/AIDS Programme

Full report available here: http://apps.who.int/iris/bitstream/handle/ 10665/70936/9789241503815_eng.pdf?sequence=1

TECHNICAL UPDATE ON TREATMENT OPTIMIZATION

PHARMACOLOGICAL EQUIVALENCE AND CLINICAL INTERCHANGEABILITY OF LAMIVUDINE AND EMTRICITABINE: A REVIEW OF CURRENT LITERATURE

				Relative	Events,	Events,
Study	Date	Reference		risk (95% CI)	Treatment	Control
Backbone regime	n identical					
Sanne	2002	[22]		1.07 (0.93, 1.24)	150/234	140/234
Benson	2004	[23]		1.07 (0.94, 1.22)	105/146	197/294
Mulenga	2013	[32]		0.95 (0.87, 1.03)	143/168	149/166
Subtotal (I-square	ed = 55.8%, p = 0.1	104)	$\langle \rangle$	1.03 (0.96, 1.10)	398/548	486/694
Daalabaaa aasimaa						
Backbone regime Martinez	2009	[26]		0.93 (0.85, 1.02)	135/167	144/166
Martin	2009	[25]		0.98 (0.94, 1.03)	169/179	171/178
Smith	2009	[27]		1.08 (0.93, 1.26)	122/188	123/205
Calza	2009	[24]		1.02 (0.94, 1.10)	41/42	45/47
Sax	2011	[9]	•	0.99 (0.94, 1.04)	242/266	244/265
Sax	2011	[9]	• +	0.96 (0.91, 1.01)	235/264	246/265
Nishijima	2013	[30]		1.00 (0.83, 1.19)	44/54	45/55
Raffi	2013	[31]	· · · · · ·	1.02 (0.94, 1.11)	142/164	209/247
Martinez	2013	[29]		1.00 (0.85, 1.17)	24/27	65/73
Martinez	2013	[29]		1.03 (0.85, 1.24)	23/27	58/70
Campo	2013	[28]		0.97 (0.88, 1.07)	130/156	133/155
Raffi	2013	[31]		0.96 (0.89, 1.04)	145/169	216/242
Subtotal (I-square	ed = 0.0%, p = 0.86	35)	\diamond	0.99 (0.96, 1.01)	1452/1703	1699/1968
Overall (I-square	d = 0.0%, p = 0.69	8)	\triangleleft	1.00 (0.97, 1.02)	1850/2251	2185/2662
		Favou	rs FTC F	avours 3TC		
Source: F	ord et al,	, 2013, PLOS ,79	3 1	1.26		

MTCT data: 3TC has been studied as a component of combination therapy for its capacity to decrease the risk of MTCT and infant mortality.

- SIMBA study (Rwanda/Uganda)
 - IAS 2003
- Mitra study (Tanzania breastfeeding study)
 - JAIDS 2008
- Kesho Bara study reported that infants of mothers treated with 3TC-containing ART during pregnancy and breastfeeding had a decreased risk of HIV transmission (43% reduction, P = 0.029), mortality, and HIV transmission or death (36% reduction, P = 0.017) at 12 months compared with mothers treated with ART that did not include 3TC
 - Lancet ID, 2011
- Infant lopinavir/r versus 3TC to prevent postnatal HIV-1 transmission: the ANRS 12174 trial
 - Kankasa C et al, CROI 2014

3TC vs FTC half-life

J Acquir Immune Defic Syndr • Volume 78, Number 2, June 1, 2018

Lamivudine for HIV Treatment

TABLE 1.	Virological,	Biochemical,	, and Pharmacologica	Characteristics of NRTIS	Used in Contem	porary HIV Therapy

	3TC	ABC	FTC	ZDV	TDF*	TAF*
HIV-1 reverse transcriptase in MT-4 cells [†] , mean (SD, n), μM ¹⁰⁴⁻¹⁰⁶	2.1 (0.6, 7)	4.0 (1.6, 21)	0.5 (NA, 2-3)	0.040 (0.005, 51)	4.2 (0.8, 2)	0.005 (0.002, 2)
Intracellular half-life, h75,107	10.5-15.5	3.3	>20	3-4	>60	NA ¹⁰⁸ ‡
Plasma or serum $T_{1/2}$, $h^{75,107,109}$	5-7	1-2	7-10	0.8-1.9	17	0.4
Reverse transcriptase Ki§ , mean (SE), nM ¹¹⁰⁻¹¹²	233 (28)	10 (1)	430 (60)	4.4 (2)	980 (NA)#	NA
Relative mtDNA content after 25 days of treatment, mean % vs untreated control cells** (SD) ^{61,113}	137 (7)	134 (27)	110 (15)	118 (24)	101 (20)	107 (16)

3TC, lamivudine; ABC, abacavir; EC₅₀, drug concentration needed to inhibit 50% of viral spread; FTC, emtricitabine; IC₅₀, half-maximal inhibitory concentration; K_i, apparent inhibitor dissociation constant; mtDNA, mitochondrial DNA; n, number of determinations; NA, not available; SD, standard deviation; SE, standard error of the mean; TAF, tenofovir alafenamide fumarate; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.

*Active moiety is tenofovir diphosphate.

[†]IC₅₀ for 3TC, ABC, FTC, and ZDV; EC₅₀ for TDF and TAF.

‡Could not be estimated.

§Inhibition constants for the triphosphate analogs of 3TC, ABC, FTC, and ZDV.

Values were generated using a homopolymeric RNA/DNA template for 3TC; DNA template for TDF, FTC, and ZDV; and RNA template for ABC.

In the form of carbovir, the active metabolite of ABC.


#Average standard error for K_i values for TDF and its analogs was 16%.

** Changes were observed after 25 days of treatment in HepG2 cells for 3TC, ABC, FTC, and ZDV; changes were observed after 10 days of treatment in MT-2 cells for TDF and TAF.

TDF/3TC conclusions from consultation

- There is indirect evidence that shows that TDF-3TC could be considered an option for countries to use for PrEP, especially where restricting PrEP drug choice to TDF/FTC would limit or prevent implementation
- Molecular structures of 3TC and FTC: Structurally related
- Mucosal PK profile suggests pharmacological equivalence of FTC and 3TC for PrEP (CDC data)
 - High concentrations in vaginal and rectal fluids with levels that are within the range seen in humans

TD*/FTC costs



Prices vary considerably in Europe with generic TD*/FTC

- IRELAND: MYLAN/TEVA (50-75 euros/month in retail pharmacies)
- SWEDEN: ACCORD (18 euros/month, covered by Swedish health system)
- GERMANY: HEXAL, RATIOPHARM (40-70 euros/month in select pharmacies)
- CROATIA: 75 euros/month, soon to drop down to 25/month (retail pharmacies)
- SWITZERLAND: RATIOPHARM (127 CHF/month in 3 pharmacies)
- ITALY: DOC 98.70 euros/month (no indication), TEVA similar price (has an indication)
- FRANCE: 5 generics in national procurement
- BELGIUM: Truvada (423 euro/month in pharmacies, while in national reimbursement individuals pay 11 euros/month). KrKA (245 euros/month) just became available

Are countries putting PrEP into their guidelines?

Sexual Health, 2018, **15**, 489–500 https://doi.org/10.1071/SH18125

Review


Going global: the adoption of the World Health Organization's enabling recommendation on oral pre-exposure prophylaxis for HIV

Ioannis Hodges-Mameletzis^{A,C}, Shona Dalal^A, Busisiwe Msimanga-Radebe^B, Michelle Rodolph^A and Rachel Baggaley^A

^AWorld Health Organization, Headquarters, Avenue Appia 20, 1202 Geneva, Switzerland.
^BWorld Health Organization, South Africa Country Office, 7th Floor Metro Park Building, 351 Francis Baard Street, Pretoria, 0002, South Africa.
^CCorresponding author. Email: yanni.hodges@gmail.com

Abstract. In September 2015, the World Health Organization (WHO) launched evidence-based guidelines by recommending that any person at substantial HIV risk should be offered oral pre-exposure prophylaxis (PrEP) containing tenofovir disoproxil fumarate (TDF) as an additional prevention choice. Since 2017, PrEP medicines have also been listed in the WHO's Essential Medicines List, including TDF/emtricitabine (FTC) and TDF in combination with lamivudine (3TC). A descriptive policy review and analysis of countries adopting WHO's 2015 recommendation on oral PrEP was conducted. As of June 2018, we identified 35 countries that had some type of policy on oral PrEP, and an additional five countries where a specific policy on PrEP is currently pending. A total of 19 high-income countries (HICs) and 21 low- and middle-income countries (LMICs) have adopted or have a pending policy.

Status of adoption of WHO's oral PrEP recommendation (situation as of June 2018)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Data Source: World Health Organization Map Production: Information Evidence and Research (IER) World Health Organization



COUNTRIES RECOMMENDING TDF/3TC

- 6 countries recommended TDF/3TC for PrEP in addition to TDF/FTC (Pakistan, South Sudan, Namibia, Kenya, Zambia, and Zimbabwe)
- Lesotho's guidelines currently recommend exclusively TDF/ 3TC
- Asia/Pacific countries addressing TDF/3TC (given cost/ supply chain)
- Europe: discussion on TDF/3TC next week at WHO EURO meeting

KEY MESSAGES

• TDF/FTC has been used most widely in clinical trials, open label extension and demonstration projects, and therefore most evidence on the safety and efficacy for PrEP is based on the use of this drug (studied across all populations, MSM, women, SDC)

- TDF/3TC can be considered as an acceptable option for PrEP in situations where access (including affordability) or availability of TDF/FTC is limited.
 - Large potential gains in rolling out PrEP, including in populations including certain pregnant women who remain at substantial risk for HIV.
 - Significant delays to such a roll out will translate into new HIV infections and loss of life.
 - There are significant opportunity costs in delaying implementation of PrEP.

CONCLUSIONS

- PrEP is highly effective, and should enhance our prevention efforts for STIs, including HIV.
- Public health argument for implementing PrEP medicines that could potentially be cost-saving to an HIV programme
- 3TC and FTC are interchangeable (for HIV treatment, PEP, and PrEP)



THANK YOU

6

(0

(0

0

0

6

U

U

Dr. Ioannis Hodges-Mameletzis WHO Geneva mameletezisi@who.int

#offerPrEP #PrEPworks